Accenture plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Accenture plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $17.60B | Oct 10, 2025 |
| FY2025 | May 31, 2025 | $17.73B | Oct 10, 2025 |
| FY2025 | Feb 28, 2025 | $16.66B | Oct 10, 2025 |
| FY2025 | Nov 30, 2024 | $17.69B | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | $16.41B | Oct 10, 2025 |
| FY2025 | May 31, 2024 | $16.47B | Oct 10, 2025 |
| FY2025 | Feb 29, 2024 | $15.80B | Oct 10, 2025 |
| FY2025 | Nov 30, 2023 | $16.22B | Oct 10, 2025 |
| FY2024 | Aug 31, 2023 | $15.99B | Oct 10, 2024 |
| FY2024 | May 31, 2023 | $16.56B | Oct 10, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.41B | Oct 10, 2025 |
| FY2025 | May 31, 2025 | $2.20B | Oct 10, 2025 |
| FY2025 | Feb 28, 2025 | $1.79B | Oct 10, 2025 |
| FY2025 | Nov 30, 2024 | $2.28B | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | $1.68B | Oct 10, 2025 |
| FY2025 | May 31, 2024 | $1.93B | Oct 10, 2025 |
| FY2025 | Feb 29, 2024 | $1.67B | Oct 10, 2025 |
| FY2025 | Nov 30, 2023 | $1.97B | Oct 10, 2025 |
| FY2024 | Aug 31, 2023 | $1.37B | Oct 10, 2024 |
| FY2024 | May 31, 2023 | $2.01B | Oct 10, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $2.05B | Oct 10, 2025 |
| FY2025 | May 31, 2025 | $2.98B | Oct 10, 2025 |
| FY2025 | Feb 28, 2025 | $2.24B | Oct 10, 2025 |
| FY2025 | Nov 30, 2024 | $2.95B | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | $2.35B | Oct 10, 2025 |
| FY2025 | May 31, 2024 | $2.63B | Oct 10, 2025 |
| FY2025 | Feb 29, 2024 | $2.05B | Oct 10, 2025 |
| FY2025 | Nov 30, 2023 | $2.56B | Oct 10, 2025 |
| FY2024 | Aug 31, 2023 | $1.91B | Oct 10, 2024 |
| FY2024 | May 31, 2023 | $2.36B | Oct 10, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $817.30M | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | $1.15B | Oct 10, 2025 |
| FY2025 | Aug 31, 2023 | $1.30B | Oct 10, 2025 |
| FY2024 | Aug 31, 2022 | $1.12B | Oct 10, 2024 |
| FY2023 | Aug 31, 2021 | $1.12B | Oct 12, 2023 |
| FY2022 | Aug 31, 2020 | $870.61M | Oct 12, 2022 |
| FY2021 | Aug 31, 2019 | $799.73M | Oct 15, 2021 |
| FY2020 | Aug 31, 2018 | $790.78M | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $704.32M | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $643.41M | Oct 24, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $11.47B | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | $9.13B | Oct 10, 2025 |
| FY2025 | Aug 31, 2023 | $9.52B | Oct 10, 2025 |
| FY2024 | Aug 31, 2022 | $9.54B | Oct 10, 2024 |
| FY2023 | Aug 31, 2021 | $8.98B | Oct 12, 2023 |
| FY2022 | Aug 31, 2020 | $8.22B | Oct 12, 2022 |
| FY2021 | Aug 31, 2019 | $6.63B | Oct 15, 2021 |
| FY2020 | Aug 31, 2018 | $6.03B | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $4.97B | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $4.67B | Oct 24, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $600.04M | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | $516.51M | Oct 10, 2025 |
| FY2025 | Aug 31, 2023 | $528.17M | Oct 10, 2025 |
| FY2024 | Aug 31, 2022 | $718.00M | Oct 10, 2024 |
| FY2023 | Aug 31, 2021 | $580.13M | Oct 12, 2023 |
| FY2022 | Aug 31, 2020 | $599.13M | Oct 12, 2022 |
| FY2021 | Aug 31, 2019 | $599.01M | Oct 15, 2021 |
| FY2020 | Aug 31, 2018 | $619.19M | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $515.92M | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $496.57M | Oct 24, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $65.39B | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | $55.93B | Oct 10, 2025 |
| FY2024 | Aug 31, 2023 | $51.25B | Oct 10, 2024 |
| FY2023 | Aug 31, 2022 | $47.26B | Oct 12, 2023 |
| FY2022 | Aug 31, 2021 | $43.18B | Oct 12, 2022 |
| FY2021 | Aug 31, 2020 | $37.08B | Oct 15, 2021 |
| FY2020 | Aug 31, 2019 | $29.79B | Oct 22, 2020 |
| FY2019 | Aug 31, 2018 | $24.45B | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | $22.69B | Oct 24, 2018 |
| FY2017 | Aug 31, 2016 | $20.61B | Oct 26, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $31.20B | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | $28.29B | Oct 10, 2025 |
| FY2024 | Aug 31, 2023 | $25.69B | Oct 10, 2024 |
| FY2023 | Aug 31, 2022 | $22.11B | Oct 12, 2023 |
| FY2022 | Aug 31, 2021 | $19.53B | Oct 12, 2022 |
| FY2021 | Aug 31, 2020 | $17.00B | Oct 15, 2021 |
| FY2020 | Aug 31, 2019 | $14.41B | Oct 22, 2020 |
| FY2019 | Aug 31, 2018 | $10.36B | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | $8.95B | Oct 24, 2018 |
| FY2017 | Aug 31, 2016 | $7.56B | Oct 26, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $22.54B | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | $21.12B | Oct 10, 2025 |
| FY2025 | Aug 31, 2023 | $15.57B | Oct 10, 2025 |
| FY2024 | Aug 31, 2022 | $13.13B | Oct 10, 2024 |
| FY2023 | Aug 31, 2021 | $11.13B | Oct 12, 2023 |
| FY2022 | Aug 31, 2020 | $7.71B | Oct 12, 2022 |
| FY2021 | Aug 31, 2019 | $6.21B | Oct 15, 2021 |
| FY2020 | Aug 31, 2018 | $5.38B | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $5.00B | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $3.61B | Oct 24, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $21.02B | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | $23.08B | Oct 10, 2025 |
| FY2024 | Aug 31, 2023 | $19.32B | Oct 10, 2024 |
| FY2023 | Aug 31, 2022 | $18.20B | Oct 12, 2023 |
| FY2022 | Aug 31, 2021 | $13.99B | Oct 12, 2022 |
| FY2021 | Aug 31, 2020 | $12.38B | Oct 15, 2021 |
| FY2020 | Aug 31, 2019 | $10.42B | Oct 22, 2020 |
| FY2019 | Sep 1, 2018 | $10.09B | Oct 29, 2019 |
| FY2019 | Aug 31, 2018 | $7.95B | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | $7.08B | Oct 24, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $11.48B | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | $5.00B | Oct 10, 2025 |
| FY2024 | Aug 31, 2023 | $9.05B | Oct 10, 2024 |
| FY2023 | Aug 31, 2022 | $7.89B | Oct 12, 2023 |
| FY2022 | Aug 31, 2021 | $8.17B | Oct 12, 2022 |
| FY2021 | Aug 31, 2020 | $8.42B | Oct 15, 2021 |
| FY2020 | Aug 31, 2019 | $6.13B | Oct 22, 2020 |
| FY2020 | Aug 31, 2018 | $5.06B | Oct 22, 2020 |
| FY2020 | Aug 31, 2017 | $4.13B | Oct 22, 2020 |
| FY2019 | Aug 31, 2016 | $4.91B | Oct 29, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 2 | Oct 10, 2025 |
| FY2025 | May 31, 2025 | 3 | Oct 10, 2025 |
| FY2025 | Feb 28, 2025 | 2 | Oct 10, 2025 |
| FY2025 | Nov 30, 2024 | 3 | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | 2 | Oct 10, 2025 |
| FY2025 | May 31, 2024 | 3 | Oct 10, 2025 |
| FY2025 | Feb 29, 2024 | 2 | Oct 10, 2025 |
| FY2025 | Nov 30, 2023 | 3 | Oct 10, 2025 |
| FY2024 | Aug 31, 2023 | 2 | Oct 10, 2024 |
| FY2024 | May 31, 2023 | 3 | Oct 10, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 2 | Oct 10, 2025 |
| FY2025 | May 31, 2025 | 3 | Oct 10, 2025 |
| FY2025 | Feb 28, 2025 | 2 | Oct 10, 2025 |
| FY2025 | Nov 30, 2024 | 3 | Oct 10, 2025 |
| FY2025 | Aug 31, 2024 | 2 | Oct 10, 2025 |
| FY2025 | May 31, 2024 | 3 | Oct 10, 2025 |
| FY2025 | Feb 29, 2024 | 2 | Oct 10, 2025 |
| FY2025 | Nov 30, 2023 | 3 | Oct 10, 2025 |
| FY2024 | Aug 31, 2023 | 2 | Oct 10, 2024 |
| FY2024 | May 31, 2023 | 3 | Oct 10, 2024 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Aug 31, 2022 | $2.46B | Oct 12, 2022 |
| FY2022 | Aug 31, 2021 | $2.24B | Oct 12, 2022 |
| FY2022 | Aug 31, 2020 | $2.04B | Oct 12, 2022 |
| FY2021 | Aug 31, 2019 | $1.86B | Oct 15, 2021 |
| FY2020 | Aug 31, 2018 | $1.71B | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $1.57B | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $1.44B | Oct 24, 2018 |
| FY2017 | Aug 31, 2015 | $1.35B | Oct 26, 2017 |
| FY2016 | Aug 31, 2014 | $1.25B | Oct 28, 2016 |
| FY2015 | Aug 31, 2013 | $1.12B | Oct 30, 2015 |